Bone Abstracts

Objectives: To confirm effect of intravenous treatment with ibandronate every three months in common population of postmenopausal women.

Methods: Patients with postmenopausal osteoporosis, who fulfil ACR criteria for postmenopausal osteoporosis and were treated with intravenous ibandronate for two years, underwent DEXA examination.

Results: A 50 women suffering from postmenopausal osteoporosis were treated with ibandronate i.v. every three during 2 years. (It means 8 doses of i.v. ibandronate.) They were examinated between May 2010 and April 2013. Average age was 71.2 years, range 47–86 years.The previous antiosteoporotic treatment had 44/50=88%.

The previous osteoporotic fracture had 28/50=56%. Average time from menopause was 21.3−9.2 years, range 0–35 years. Average time of previous antiosteoporotic treatment was 3.3−0.5 years, range 0–16 years.

BMD (g/cm²)Trend New fractures 0

L spine +3.3% after 1 year,

+1.9% after 2 years

hip +0.5\.+0.9%,

neck +2.7\.+3.3%

Difference (T-score) after 1 year Difference (T-score) after 2 years compare to baseline

L-spine: P=0.23 L-spine: P=0.23

total hip: P=0.22 total hip: P=0.95

neck: P=0.001 neck: P < 0.0001

There was no difference in all regions between the first and secon years.

Difference (g/cm²) after 1 year Difference (g/cm²) after 2 years

L-spine: P=0.004 L-spine: P=0.009

hip: P=0.933 hip: P=0.96

neck: P=0.004 neck: P=0.18

There was no difference in all regions between the 1 and 2 years.

Conclusion: These results of common population of postmenopausal women confirm BMD gain in all regions especially after the 1 year of treatment, but significant gain in T-score and g/cm² was only in femur neck and significant gain in g/cm² was also in L spine. After the first year there was stagnation.

Postmenopausal osteoporosis, BMD, T-score, ibandronate